Clinical trial · Interventional
Selective Treatment According to Molecular Subtype of Prostate Cancer
NCT03696186CI-TRIAL-00035199STAMPunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers. Depending on the expression of these markers, the patients will be characterize as group 1 (Luminal phenotype), group 2 (Neuroendocrine phenotype) or group 3 (Atypical phenotype) and a random assignment will be performed to standard or experimental treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Castration-resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma | ALIAS | 0.90 |
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atypical type-1 | Drug | — | UNRESOLVED |
| Atypical type-2 | Drug | — | UNRESOLVED |
| Luminal type-1 | Drug | — | UNRESOLVED |
| Luminal type-2 | Drug | — | UNRESOLVED |
| Neuroendocrine type-1 | Drug | — | UNRESOLVED |
| Neuroendocrine type-2 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- ACTIVE_COMPARATOR
- label
- Luminal type-1
- description
- Standard treatment
- interventionNames
- Drug: Luminal type-1
- type
- EXPERIMENTAL
- label
- Luminal type-2
- description
- Experimental treatment
- interventionNames
- Drug: Luminal type-2
- type
- ACTIVE_COMPARATOR
- label
- Neuroendocrine type-1
- description
- Standard treatment
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants who have given consent form; 2. Patients with a confirmed diagnosis of mCRPC according to EAU 2018 guideline; 3. Serum testosterone must reach castration level: \<50 ng per deciliter; 4. Participants with life expectancy of at least 6 months based on the Investigator's clinical judgment. Exclusion Criteria: 1. Participants who are allergic to contrast medium; 2. Patients were excluded if they planned to receive additional concurrent anticancer therapies; 3. Patients doesn't sign an informed consent form.
References
Publications (0)
Data not yet available
No reference posted for this study.